Search

Search Constraints

You searched for: Author/Creator Platzbecker, U.

Search Results

1. 100 INTERNATIONAL, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH IPSS INTERMEDIATE-1 MYELODYSPLASTIC SYNDROMES WITH RBC-TRANSFUSION-DEPENDENT ANEMIA AND THROMBOCYTOPENIA: THE QUAZAR LOWER-RISK MDS TRIAL. Issue 1 (April 2015)

3. 109 CLINICAL AND MOLECULAR PREDICTORS OF RESPONSE TO ERYTHROPOIESIS STIMULATING AGENTS (ESA) IN LOWER RISK MDS PATIENTS. (April 2015)

4. 112 RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS). (April 2015)

5. 117 A PHASE 3 STUDY OF LENALIDOMIDE VERSUS PLACEBO IN RBC TRANSFUSION-DEPENDENT (TD) PATIENTS WITH LOWER-RISK MDS WITHOUT DEL(5Q) UNRESPONSIVE OR REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS). Issue 1 (April 2015)

6. 120 RESULTS OF THE MULTICENTER, PHASE II STUDY OF THE SAFETY OF LENALIDOMIDE MONOTHERAPY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH AN ISOLATED DEL(5Q). Issue 1 (April 2015)

7. 240 DYSPLASIAS REVISITED – CONSIDERATIONS FOR A MULTIDIMENSIONAL APPROACH TO HETEROGENEITY OF MDS: DATA ON 1979 PATIENTS FROM THE GERMAN AUSTRIAN DATA BASE. Issue 1 (April 2015)

9. 37 CAR, A NOVEL MEDIATOR OF ERYTHROID DIFFERENTIATION AND MIGRATION, IS SPECIFICALLY DOWNREGULATED IN ERYTHROPOIETIC PROGENITOR CELLS IN MDS. (April 2015)

10. 53 LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM A PHASE 2 STUDY. (April 2015)